3.43
-13.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Passage Bio
From its filings with the US Securities and Exchange Commission
Passage Bio is based in Philadelphia, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PASG. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $45.5m. At that date it held total assets of $62.3m and shareholders' equity of $18.8m.
We are a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. We believe we have developed a differentiated approach to developing treatments for central nervous system, or CNS, disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success.
Our lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 is a gene replacement therapy that utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, or GRN, encoding progranulin, or PGRN, to the brain via intra cisterna magna, or ICM, administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. We believe this clinical product candidate has the potential to provide patients with significantly improved outcomes given the rigorous capsid and transgene selection process, and our chosen route of ICM administration, which provides the potential for enhanced benefits due to widespread vector delivery to the brain and spinal cord and an improved safety profile compared with systemic administration, due to the lower doses required.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Feb 2020
- Employees
- 24
- Website
- passagebio.com ↗
- Head office
- ONE COMMERCE SQUARE, PHILADELPHIA, PA, 19103
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Maxine GowenIndependent Chairwoman of the Board, since 2021$128,000
- Mr. William ChouPresident, Chief Executive Officer, Director, since 2022$1.6m
- Ms. Kathleen BorthwickChief Financial Officer$861,698
- Mr. Edgar CaleGeneral Counsel, Company Secretary$881,920
- Dr. Athena CountouriotisIndependent Director$100,197
- Mr. Sandip KapadiaIndependent Director$100,000
- Mr. Thomas KassbergIndependent Director$104,586
- Dr. Derrell PorterIndependent Director$94,000
- Dr. Dolan SondhiIndependent Director$80,885
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 51
- Social
- 72
- Governance
- 27
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Passage Bio Inc develops six AAV-delivered therapeutics for rare monogenic central nervous system diseases.
- The firm focuses on transformative therapies targeting gangliosidosis, frontotemporal dementia, and Krabbe disease.
- PBGM01 utilizes an AAVhu68 capsid to deliver a functional GLB1 gene to the brain.
Weaknesses
- The company currently employs only 24 full-time staff members in the United States.
- Passage Bio Inc operates with a very small workforce of 20 full-time employees.
- The firm has a limited number of employees compared to larger biotechnology competitors.
Opportunities
- PBFT02 utilizes an AAV1 capsid to deliver a functional GRN gene for frontotemporal dementia treatment.
- PBKR03 utilizes an AAVhu68 capsid to deliver a functional GALC gene for Krabbe disease.
- The company can expand its portfolio of life-transforming genetic medicines for central nervous system disorders.
Threats
- The firm went public on 28 February 2020, which may create market volatility pressures.
- Passage Bio Inc faces risks associated with developing therapies for rare monogenic diseases.
- The small employee count of 24 may limit the company's operational capacity and growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.